<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Br J Pharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">Br. J. Pharmacol</journal-id>
<journal-id journal-id-type="doi">10.1111/(ISSN)1476-5381</journal-id>
<journal-id journal-id-type="publisher-id">BPH</journal-id>
<journal-title-group>
<journal-title>British Journal of Pharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0007-1188</issn>
<issn pub-type="epub">1476-5381</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29791744</article-id>
<article-id pub-id-type="pmc">6016627</article-id>
<article-id pub-id-type="doi">10.1111/bph.14338</article-id>
<article-id pub-id-type="publisher-id">BPH14338</article-id>
<article-id pub-id-type="other">2017-BJP-1415-RP.R1</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Research Paper</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Research Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>PF‐06526290 can both enhance and inhibit conduction through voltage‐gated sodium channels</article-title>
<alt-title alt-title-type="right-running-head">Multiple modes of Na<sub>v</sub> channel modulation by PF‐06526290</alt-title>
<alt-title alt-title-type="left-running-head">L Wang et al.</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" id="bph14338-cr-0001">
<name>
<surname>Wang</surname>
<given-names>Lingxin</given-names>
</name>
<xref ref-type="aff" rid="bph14338-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bph14338-cr-0002">
<name>
<surname>Zellmer</surname>
<given-names>Shannon G</given-names>
</name>
<xref ref-type="aff" rid="bph14338-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bph14338-cr-0003">
<name>
<surname>Printzenhoff</surname>
<given-names>David M</given-names>
</name>
<xref ref-type="aff" rid="bph14338-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" id="bph14338-cr-0004">
<name>
<surname>Castle</surname>
<given-names>Neil A</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2653-4794</contrib-id>
<address>
<email>ncastle@icagen.com</email>
</address>
<xref ref-type="aff" rid="bph14338-aff-0002">
<sup>2</sup>
</xref>
</contrib>
</contrib-group>
<aff id="bph14338-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Molecular and Cellular Physiology</named-content>
<institution>Stanford University</institution>
<named-content content-type="city">Stanford</named-content>
<named-content content-type="country-part">CA</named-content>
<country country="US">USA</country>
</aff>
<aff content-type="private-address" id="bph14338-aff-0002">
<label><sup>2</sup></label>
<institution>Icagen Inc.</institution>
<named-content content-type="city">Durham</named-content>
<named-content content-type="country-part">NC</named-content>
<named-content content-type="post-code">27703</named-content>
<country country="US">USA</country>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold> Neil A. Castle, Work, Pfizer Inc. (currently Icagen Inc.), 4222 Emperor Boulevard, Durham, NC 27703, USA. E‐mail: <email>ncastle@icagen.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>03</day>
<month>6</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>7</month>
<year>2018</year>
</pub-date>
<volume>175</volume>
<issue>14</issue>
<issue-id pub-id-type="doi">10.1111/bph.v175.14</issue-id>
<issue-title content-type="special-issue-title">Themed Section: Emerging Areas of Opioid Pharmacology. Guest Editors: Eamonn Kelly, Graeme Henderson and Chris P Bailey</issue-title>
<fpage>2926</fpage>
<lpage>2939</lpage>
<history>
<date date-type="received">
<day>14</day>
<month>11</month>
<year>2017</year>
</date>
<date date-type="rev-recd">
<day>06</day>
<month>3</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>17</day>
<month>3</month>
<year>2018</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2018 The British Pharmacological Society <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2018 The British Pharmacological Society</copyright-statement>
</permissions>
<self-uri content-type="pdf" xlink:href="file:BPH-175-2926.pdf" xlink:type="simple"></self-uri>
<abstract>
<sec id="bph14338-sec-0001">
<title>Background and Purpose</title>
<p>Pharmacological agents that either inhibit or enhance flux of ions through voltage‐gated sodium (Na<sub>v</sub>) channels may provide opportunities for treatment of human health disorders. During studies to characterize agents that modulate Na<sub>v</sub>1.3 function, we identified a compound that appears to exhibit both enhancement and inhibition of sodium ion conduction that appeared to be dependent on the gating state that the channel was in. The objective of the current study was to determine if these different modulatory effects are mediated by the same or distinct interactions with the channel.</p>
</sec>
<sec id="bph14338-sec-0002">
<title>Experimental Approach</title>
<p>Electrophysiology and site‐directed mutation were used to investigate the effects of PF‐06526290 on Na<sub>v</sub> channel function.</p>
</sec>
<sec id="bph14338-sec-0003">
<title>Key Results</title>
<p>PF‐06526290 greatly slows inactivation of Na<sub>v</sub> channels in a subtype‐independent manner. However, upon prolonged depolarization to induce inactivation, PF‐06526290 becomes a Na<sub>v</sub> subtype‐selective inhibitor. Mutation of the domain 4 voltage sensor modulates inhibition of Na<sub>v</sub>1.3 or Na<sub>v</sub>1.7 channels by PF‐06526290 but has no effect on PF‐06526290 mediated slowing of inactivation.</p>
</sec>
<sec id="bph14338-sec-0004">
<title>Conclusions and Implications</title>
<p>These findings suggest that distinct interactions may underlie the two modes of Na<sub>v</sub> channel modulation by PF‐06526290 and that a single compound can affect sodium channel function in several ways.</p>
</sec>
</abstract>
<counts>
<fig-count count="8"></fig-count>
<table-count count="0"></table-count>
<page-count count="14"></page-count>
<word-count count="7111"></word-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>component-id</meta-name>
<meta-value>bph14338</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>July 2018</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.4.1.1 mode:remove_FC converted:25.06.2018</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<p content-type="self-citation">
<mixed-citation id="bph14338-cit-0001" publication-type="journal">
<string-name>
<surname>Wang</surname>
<given-names>L.</given-names>
</string-name>, <string-name>
<surname>Zellmer</surname>
<given-names>S. G.</given-names>
</string-name>, <string-name>
<surname>Printzenhoff</surname>
<given-names>D. M.</given-names>
</string-name>, and <string-name>
<surname>Castle</surname>
<given-names>N. A.</given-names>
</string-name> (<year>2018</year>) <article-title>PF‐06526290 can both enhance and inhibit conduction through voltage‐gated sodium channels</article-title>, <source xml:lang="en"/>British Journal of Pharmacology, <volume>175</volume>, <fpage>2926</fpage>–<lpage>2939</lpage>, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/bph.14338">https://doi.org/10.1111/bph.14338</ext-link>.</mixed-citation>
</p>
</notes>
</front>
</article>
</pmc-articleset>